Pharmaceutical Market Europe • September 2022 • 3
COMMENT
In this issue, our cover article focuses on the importance of patient support programmes (PSPs) and how they are key to improving patient health.
As Danny Buckland writes in his article on page 30, PSPs are integral to therapy design and patient outcomes, and are the foundations that will make pharma’s new era function and thrive. They are the multipurpose building blocks that improve patient safety, pharmacovigilance, trial enrolment and retention, disease management, adherence, market share and quality of life for patients. They have proliferated in recent years and are becoming increasingly adept at tailoring content for individual patients to cope with complex regimens and engaging with diverse and hard-to-reach communities.
Turn to page 24 to read Rich Quelch’s article on the importance of future-proofing pharma supply chains by improving inefficiencies in global health architecture. With the threat of more global pandemics in the future a certainty, not a question, these inefficiencies need to be addressed. Rich looks at the key lessons COVID-19 has taught us and how the international community can work together more closely to ensure future pandemic preparedness.
Despite being overshadowed by the pandemic, the fight against antimicrobial resistance continues., In this issue, Jonathan Cooke talks about how antibiotics that all but eradicated tuberculosis from Europe have lost their potency, leaving the world vulnerable to a disease that still infects 10 million people a year and is already the second leading infectious killer after COVID-19. Read more on page 16.
Looking ahead, our October issue will look at UK market access. Market access is about getting the right treatment to the right patient at the right time, but enabling faster patient access to therapies remains a key challenge for pharma companies.
If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Journalist/editorial assistants
Fleur Jeffries and Emily Kimber
Studio:
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2022 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW